Completed

A Randomized Phase III Trial for Evaluation of Usefulness of Pelvic Drains After Radical Hysterectomy and Node Dissection (RHND)

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

infection prophylaxis and management

+ management of therapy complications

+ surgical procedure

Procedure
Who is being recruted

Urogenital Diseases+17

+ Genital Diseases

+ Uterine Cervical Diseases

See all eligibility criteria
How is the trial designed

Supportive Care Study

Phase 3
Interventional
Study Start: February 1998
See protocol details

Summary

Principal SponsorEuropean Organisation for Research and Treatment of Cancer - EORTC
Last updated: July 11, 2012
Sourced from a government-validated database.Claim as a partner

Study start date: February 1, 1998

Actual date on which the first participant was enrolled.

OBJECTIVES: I. Evaluate postoperative complications associated with the use or omission of pelvic drains following radical hysterectomy and node dissection that includes suturing of the vaginal cuff and no peritonealization. OUTLINE: This is a randomized, two-arm study. All patients receive radical hysterectomy (Rutledge-Piver II-III type) and pelvic lymphadenectomy, without pelvic and parietal peritonealization, with suturing of the vaginal cuff and closure of fascia and cutaneous layers; lumboaortic node dissection is optional. Patients are randomized during surgery to one of two arms: those on arm I receive pelvic drains and those on arm II do not. Those in arm I have drains applied in the pelvis, and lymph is collected by vaginal and/or transabdominal drains located in both retroperitoneal fossa. Drains are removed when the loss is less than 50 mL in 24 hours. Patients in both arms are followed at 2-3 months and 12 months after surgery. PROJECTED ACCRUAL: 214 patients will be accrued for this study within 2 years.

NCT00003267
Principal SponsorEuropean Organisation for Research and Treatment of Cancer - EORTC
Last updated: July 11, 2012
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

214 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Supportive Care Study

These studies explore ways to improve comfort and daily life for people living with a condition. They may focus on easing symptoms, reducing treatment side effects, or supporting overall well-being.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesGenital DiseasesUterine Cervical DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsGenital Diseases, FemaleGenital Neoplasms, FemaleNeoplasmsNeoplasms by SitePathologic ProcessesPathological Conditions, Signs and SymptomsUrogenital NeoplasmsUterine DiseasesUterine NeoplasmsVaginal DiseasesFemale Urogenital DiseasesUterine Cervical NeoplasmsInfectionsPostoperative ComplicationsVaginal NeoplasmsEndometrial Neoplasms

Criteria

DISEASE CHARACTERISTICS: Histologically proven cervical, vaginal, or endometrial carcinoma for which abdominal radical hysterectomy (Rutledge-Piver II or III type) and pelvic node dissection is indicated The following are excluded: Extensive intraoperative retroperitoneal blood loss (more than 3000 mL) Excessive postsurgical hemorrhage or oozing of the wound area requiring postoperative drainage Concurrent urinary or bowel injury/deviation or surgical procedures for urinary incontinence (Burch etc.) Application of prophylactic abdominal mesh for subsequent radiotherapy PATIENT CHARACTERISTICS: Age: Not specified Performance status: WHO 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not pregnant PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior neoadjuvant chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery: See Disease Characteristics

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 18 locations

Kaiser Franz Josef Hospital

Vienna (Wien), AustriaOpen Kaiser Franz Josef Hospital in Google Maps

Universitair Ziekenhuis Antwerpen

Edegem, Belgium

U.Z. Gasthuisberg

Leuven, Belgium

Institut Gustave Roussy

Villejuif, France
Completed18 Study Centers